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ABSTRACT  
The principal objective behind the writing of this article on the floating drug delivery system (FDDS) was to systematize the recent literature with 
the core process of floatation in acquiring gastric retention. The different strategies used in the development of FDDS by constructing the 
effervescent and noneffervescent type of floating tablets basis of which is buoyancy mechanism. FDDS is a method to deliver the drugs that are 
active locally with a narrow absorption window in the upper gastrointestinal tract, unstable in the lower intestinal environment, and possess low 
solubility with higher pH values. The novel methodologies in FDDS include approaches to design a single unit and multiple-unit floating systems, the 
physiological and formulation variability affecting gastric retention along with the use of recently invented and developed polymers. This review 
also focuses on various in vitro techniques and in vivo studies in view of performance and application of floating systems. Floating dosage forms can 
be delivered in conventional forms like tablets, capsules with the addition of suitable ingredients along with the gas generating agent. This review 
also throws light on different techniques used in developing floating dosage forms along with current and novel advancements. 
Keywords: Floating drug delivery systems, Gastric retention, Mechanism, Single unit, Multiple units 




Floating drug delivery systems (FDDS) are invented to retain the 
drug in the stomach and applicable for drugs with poor solubility 
and low stability in intestinal fluids. The basis behind FDDS is 
making the dosage form less dense than the gastric fluids to make it 
float on them. FDDS are hydro-dynamically controlled low-density 
systems with sufficient buoyancy to float over the gastric contents 
and remain buoyant in the stomach without affecting the gastric 
emptying rate for a prolonged period of time. The residual system is 
emptied from the stomach with the release of the drug. This results 
in enhanced gastric residence time and good control over plasma 
drug concentration fluctuations. The principle of buoyant 
preparation offers a simple and practical approach to achieve 
increased gastric residence time for the dosage form and sustained 
drug release [1]. Prolonging the gastric retention of a delivery 
system is desirable for achieving the greater therapeutic efficacy of 
the drug substance under certain circumstances. For example, drugs 
which show better absorption at the proximal part of the 
gastrointestinal tract and drugs with low solubility and get degraded 
in alkaline pH found efficient in prolonging gastric retention. In 
addition, for sustained drug delivery to the stomach and proximal 
small intestine in treating certain ulcerative conditions, prolong 
gastric retention of the therapeutic moiety and hence offer 
numerous advantages including improved bioavailability and 
therapeutic efficacy with reduction of dosing frequency [2]. Fig. 1 
describes the classification of FDDS with consideration of its 
physiochemical behavior and appearance. 
 
 
Fig. 1: Classification of floating drug delivery system (FDDS) 
 
This review article is written based on the literature available from 
1991 to 2018 and collected by different sources like Pubmed, Google 
search, Directory of Open Access Journals, Science direct etc. using 
key words like Floating drug delivery systems, gastric retention, 
mechanism, single unit, multiple units. 
Advantages of floating drug delivery system  
Floating dosage systems are delivery systems with gastric retentive 
behavior and offer several advantages in drug delivery. Some of 
these include:  
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1. Simple and conventional technique for formulation.  
2. Site-specific drug delivery. 
3. Controlled delivery of drugs.  
4. Delivery of drugs for residual action at a specific site in the stomach.  
5. Improved drug absorption with increased GRT and excess 
duration of contact of dosage regimen at its target site.  
6. Minimizing irritation of GIT mucosa by the drugs with slow 
release rate. Acidic drug substances like aspirin cause irritation to 
gastric mucosa as it comes in contact. Hence HBS formulation would 
be beneficial in administration of aspirin and other similar drugs. 
Administration of prolonged release floating dosage forms, tablet or 
capsules, causes dissolution of the drug in the gastric fluid. They 
dissolve in the gastric fluid before getting absorbed in the small 
intestine with emptying stomach contents. Hence it is expected that 
a drug will be fully absorbed from floating dosage forms if it remains 
in the solution form even at the alkaline pH of the intestine. 
7. When there would be vigorous intestinal movement with short 
transit time, it might result in a certain type of diarrhea hence poor 
absorption is expected. Under such conditions, it is advantageous to 
maintain the drug in floating condition in the stomach for better 
efficacy. 
8. In treating gastroesophageal reflux disorders (GERD). 
9. Ease of administration with higher patient compliance.  
The floating drug delivery system also carries certain disadvantages 
which limit its applicability [3]. 
Disadvantages of floating drug delivery system  
1. The major disadvantage of a floating system is due to the 
necessity of a sufficient level of gastric fluids to float without a sink. 
However, this limitation can be overcome by coating the dosage 
form with bio adhesive polymers that easily adhere to gastric 
mucosa. 
2. The drugs those get significantly absorbed throughout 
gastrointestinal tract, with significant first-pass metabolism, are 
desirable candidate predominantly. 
3. Certain drugs present in the floating system may causes irritation 
to gastric mucosal linings.  
4. Gastric emptying of floating systems may occur at random and 
highly dependent on its dimensions. Therefore patients should not 
have dosage prior going to bed.  
Table 1 illustrates different parameters in the differentiation of 
Conventional v/s Gastro retentive drug delivery system 
  
Table 1: Conventional v/s gastroretentive drug delivery system 
Relative parameters Conventional drug delivery system Gastro retentive drug delivery system References 
Toxicity High risk of toxicity Very low risk of toxicity [3] 
Patient compliance Low Improved [3] 
Drugs with poor 
solubility and high pH 
Not suitable for delivery of drugs with narrow 
absorption window in the Small intestine region 
Suitable for delivery of drugs with narrow 
absorption window in the small Intestine region. 
[4] 
Drugs acting locally 
acting in the stomach 
Not much advantageous for drugs having rapid 
absorption through GIT 
Very much advantageous of drugs acting locally 
in the stomach. 
[4] 
Dose dumping No risk of dose dumping. Possibility of dose dumping [3] 
 
Physiological considerations 
Different physiological factors such as pH, gastric enzymes, nature 
and volume of gastric secretions, residence time, and effective 
absorbing surface area at the site of delivery contribute the major 
role in drug execution and absorption. The gastric pH frequently 
affects the performance of orally administered drug and it is 
influenced by various factors like diet, disease, the presence of gases, 
fatty acids and other fermentation products in the stomach. Radio 
telemetry has been successfully used in measuring the 
gastrointestinal pH in a human being. The reported mean value of 
gastric pH in fasted healthy subjects is 1.1±0.15, and the mean 
gastric pH in fed state in healthy males has been reported to be 
3.6±0.4. This pH returns to the basal level in about 2 to 4 h.  
Age is the second factor and pathological conditions which influence 
gastric pH. About 20% of the elderly people exhibit either 
diminished (hypochlorhydria) or no gastric acid secretion 
(achlorhydria) leading to basal pH value over 5.0. Pernicious 
anaemia and AIDS are the syndromes in which there is significantly 
reduction in gastric acid secretion leading to elevated gastric pH. 
Administration of drugs like H2 receptor antagonist and proton 
pump inhibitors significantly reduce gastric acid secretion. The 
mean pH value in fasted duodenum has been reported to be 5.8±0.3 
in healthy subjects, and the fasted small intestine pH is reported to 
be 6.0±0.14. Normal gastric time usually ranges between 5 min to 2 
h. In consideration of fasted and fed condition of the stomach, two 
distinct patterns of gastrointestinal motility and secretions have 
been studied. In a fasted state the electrical activity of the 
gastrointestinal tract is evidenced by some cyclic contractile events, 
in the medical language, it is known as migrating myoelectric 
complexes (MMC) [5].  
There are four successive phases of MMC activity as- 
Phase I–period of no contraction (30 to 60 min)  
Phase II– a period of intermittent contractions (20–40 min).  
Phase III– a period of regular contractions at the maximal frequency 
that travels distally also known as housekeeper wave (10 to 20 min)  
Phase IV–period of transition between phase III and phase I (0 to 5 min).  
These cycles are retarded by feeding and results into irregular 
contractile activities which may last for 3 to 4 h. Thus frequent 
feeding results in prolonging gastric residence time. Another 
crucial factor in affecting the gastric emptying is the caloric 
presence in the meals. Fatty and lipoidal contents are emptied at a 
slower rate than other contents. Acidity and osmolality also 
contribute major role in lowering the gastric emptying. Stress 
considered as a factor in gastric emptying rate, while depression 
lowers it. In general, women and the elderly have a slower 
emptying rate than men and young people respectively. In 
addition, exercise and body posture also affect the gastric 
emptying. Apart from these physiological constraints other factors 
like size and density of the dosage form also contribute major role 
in gastrointestinal emptying. Dosage forms possessing low dense 
character than that of gastric fluid does have properties of floating 
behavior and gastric retention. A density of<1.0 gm/cm3 is 
necessary for floating phenomenon. Dosage forms with a diameter 
more than 7.5 mm exhibits a better gastric residence time [5]. 
Criteria selection of drug candidate for the floating drug 
delivery system  
1. Readily absorption via upper gastrointestinal tract.  
2. Drugs with low pKa, that does exhibit unionized characters  
3. Drugs are possessing lower solubility at higher pH. 
4. Effect of local action of drugs e. g. treating Helicobacter pylori in 
treatment of ulcerative conditions.  
5. Drugs which get degraded in alkaline pH conditions; 
bioavailability of those can be enhanced by fabricating into gastro-
retentive forms. 
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6. Minimizing gastric irritation as it may result in the increase of 
drug concentration level in the stomach. [6, 7] 
Limitations of floating drug delivery system  
1. FDDS need to be administered after the meal but the residence 
and emptying time of drugs depends upon the digestive state which 
affects its absorption. 
2. Floating ability depends on the hydration state of the dosage 
form. It is necessary of administration of water intermittent (a 
tumbler full, every 2 h) to keep these tablets floating in vivo.  
3. Floating ability of drug in the stomach depends upon the person 
being positioned.  
4. Drugs with solubility or stability problems with the gastric fluid 
are not a suitable candidate for FDDS. 
5. Certain drugs though readily get absorbed in the stomach with 
successful first pass metabolism are not suitable as slow gastric 
emptying may lead to the reduced systemic bio-availability e. g. 
Nifedipine [4, 6, 7]. 
Application of floating drug delivery system  
1. FDDS are claimed for the increased efficacy of drugs as recent 
studies show that the administration of Diltiazem floating tablets twice a 
day would be more effective compared to normal tablets in hypertensive 
patients. 
2. In case of Parkinson patient, FDDS is effective in absorption of the 
drug over a period of 6-8 h and maintained substantial plasma 
concentration.  
3. FDDS is site-specific drug delivery: These systems are 
particularly advantageous for drugs that are specifically absorbed 
from the stomach or the proximal part of the small intestine, e. g., 
Riboflavin and Furosemide. 
4. FDDS served as an excellent drug delivery system in the eradication 
of Helicobacter pylori, blamed for chronic gastritis and peptic ulcers.  
5. FDDS are perfect HBS dosage form to provide better delivery of 
drugs and reduced its GI side effects. [6-8] 
Table 2 shows the different polymers used in the floating drug 
delivery system and their effects 
  
Table 2: View of different polymers used and their effect in floating 
Drug Polymer used Floating effect Reference 
Ondansetron EudragitS100 The drug release rate and floating behavior both were reported good [9] 
Captopril Eudragit A good floating behavior was observed, whereas the dissolution rate was found 
to be slow, because of the low solubility of Eudragit at acidic pH 
[10] 
Risperidone Eudragit A good floating behavior was observed, whereas the dissolution rate was found 
to be slow, because of the low solubility of Eudragit at acidic pH 
[11] 
Ofloxacin Eudragit The floating was reported for more than 24 h. [12] 
Cephalexin HPMC Longer gastric residence time and improved bioavailability [13] 
Hydralazine HPMC Sustained release pattern with good swelling index and floating effect [14] 
Simvastatin HPMC More sustained drug release with high buoyancies [15] 
Cefpodoxime 
proxetil 
HPMC-Guar gum Floating lag time enhanced with an increase in swelling behavior [16] 
Atenolol HPMC-Locust bean gum Follows zero order kinetics with prolonging the gastric residence time [17] 
Diltiazem Sodium alginate beads Sustained drug delivery over a period of time with a reduction in dose frequency [18] 
Ranitidine Polyacrylate, HPMC and 
chitosan gel 
Sustained drug delivery with increased swelling behavior [19] 
Ciprofloxacin EC and HPMC Increased gastric residence time with a decrease in dose amount and interval [20] 
Propranolol  Polyvinyl acetate Follows zero order kinetics with lowering gastric emptying time [21] 
 
Classification of floating drug delivery systems  
(A) Effervescent system floating drug delivery system  
These are particular drug delivery system made up of matrix type 
and a swellable polymer such as methylcellulose and chitosan along 
with effervescent compounds viz. sodium bicarbonate, tartaric acid, 
citric acid. These are formulated in such a specific way as once it 
comes in contact with gastric juice; co2 gets liberated with 
entrapment in swollen hydrocolloid to provide buoyancy for dosage 
form. The basis of the delivery system is on swellable asymmetric 
triple layer tablet approach design [22-24]. 
(B) Gas generating systems 
Low-density FDDS is based on the release of co2 upon contact with 
gastric fluids after oral administration. The materials are formulated 
in such a way that after entering in the stomach, co2 is librated due to 
reaction with acidic gastric content and which get entrapped in the 
gel-based hydrocolloid (fig. 2). It produces an upward motion of the 
dosage form and maintains its buoyancy. Ultimately it causes a 
decrease in specific gravity of dosage form and hence resulting into a 
float on the chime. The co2 generating components are mixed within 
the tablet matrix in a single layer or multi-layered form to produce 
gas generating mechanism in hydrocolloid layer, and the drug in the 
other layer results into a sustained release effect [22, 25]. 
(II) Volatile liquid containing systems (Osmotically controlled 
drug delivery system) 
This is an osmotically controlled floating system in which a device 
comprised of a hollow deformable unit in convertible collapsed 
form. Housing would be attached to its deformable unit and 
internally divided into a first and second chamber separated by an 
impermeable, pressure sensitive movable unit. The first chamber 
usually contains an active drug, while the second a volatile liquid, 
such as cyclopentane or ether get vaporized at a physiological 
temperature to produce a gas, enabling the drug reservoir to float. 
The unit gets expelled from the stomach, with the help of 
bioerodible plug that allowed the vapour to escape [22, 25]. 
 
Fig. 2: Mechanism of floatation via CO2 liberation 
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(B) Non-effervescent FDDS 
Non-Effervescent Floating Drug Delivery Systems comprises a gel-forming 
(or) swellable cellulose type of hydrocolloids made up of polysaccharide 
along with matrix forming polymers like polycarbonate, polymethacrylate, 
and polystyrene. The routine formulation method involves the mixing of 
the drug with gel forming hydrocolloids that swell in contact with gastric 
fluid upon oral administration and maintains the integrity of shape and a 
bulk density barrier, the air trapped by swollen polymer confer buoyancy 
to the dosage forms [22, 25]. 
(I) Colloidal gel barrier systems (Hydrodynamic balanced systems) 
This system prolongs gastric retention time and maximizes the 
amount of drug that reaches its absorption site in the solution form. It 
essentially contains drug with gel-forming hydrocolloids to remain 
buoyant on the stomach content. Such a system incorporates one or 
more gel-forming cellulose type hydrocolloid e. g. hydroxypropyl 
methylcellulose (HPMC), polysaccharides and matrix forming 
polymers such as polycarbophil, polystyrene, and polyacrylate. Upon 
contact with gastro-Intestinal (GI) fluid, the hydrocolloid in the system 
hydrates to generate a colloid gel barrier to its surrounding [22, 25]. 
(II) Microporous compartment systems 
This technology incorporates the encapsulation technique of a drug 
reservoir inside a microporous compartment along with pores at top 
and bottom walls. The peripheral wall of the drug reservoir 
compartment is completely sealed to prevent any direct contact of 
the gastric surface with the undissolved drug. In the stomach, the 
floatation chamber composed of entrapped air causes the delivery 
system to float over the gastric content. Gastric fluid enters through 
the aperture, to the extent that it prevents theirs exist from the drug 
and carrier the dissolved drug for continuous transport across the 
intestine for absorption [25]. 
(III) Floating Microspheres/Micro balloons 
Hallow microspheres also are known as micro balloons are 
considered as a most efficient buoyant system. It is composed of 
central hallow space inside the microsphere. Hallow microsphere is 
loaded with a drug in their outer polymer shelf are fabricated by a 
novel solvent Diffusion method for emulsion [24]. 
(IV) Alginate beads/Floating beads 
Multi-unit floating dosage forms have been developed from calcium 
alginate spherical beads of about 2.5 mm in diameter and can be 
fabricated by adding sodium alginate solution into aqueous solution 
of calcium chloride, resulting in the precipitation of calcium alginate, 
the beads are further separated, snap-frozen in liquid nitrogen and 
freeze-dried at 400 °C for 24 h, leads to generation of a porous 
system. This fabricated system would maintain a floating force for 
over 12 h and these floating beads provide a longer residence time 
of more than 5.5 h [25]. 
(C) Raft-forming systems 
Raft-forming systems are in much attention for the delivery of antacid 
and drug delivery for gastro infection and disorders. On contact with 
gastric fluid, a gel-forming solution swells and forms a viscous cohesive 
gel entrapped with co2 bubbles which generate raft layer on top of 
gastric fluid, thus facilitates releases drug slowly in the stomach [25]. 
Drugs which are prepared in the floating drug delivery system and 
their types of dosage forms are given in the table 3. 
 
Table 3: List of drugs explored in floating dosage forms 
Types of 
dosage forms 
Drugs explored in floating dosage forms References 
Microspheres Aspirin, Griseofulvin, P-nitroaniline, Ibuprofen, Ketoprofen, Terfenadine, Tranilast. [6] 
Granules Diclofenac sodium, Indomethacin, Prednisolone. [6, 8] 
Films Cinnarizine, (capsules) [8] 
Capsules Chlordiazepoxide HCl, Diazepam, Furocemide, L-Dopa and Benserazide, Misoprostol, Nicardipine, Propranolol 
HCl, Ursodeoxychoric acid 
[6, 8, 10] 
Tablets/Pills Acetaminophen, Aspirin, Amoxycillin trihydrate, Ampicillin, Atenolol, Captopril, Ciprofolxacin, Chlorpheniramine 
maleate, Cinnarizine, Furosemide, 5-Fluorouracil, Isosorbide mononitrate, Diltiazem, Isosorbide dinitrate, 
Nimodipine, Para amino benzoic acid, Prednisolone, Quinidine, Varapamil HCl, Riboflavin, Sotalol. 
[6, 8, 10] 
Alginate beads Diclofenac sodium, Famotidine, Nevirapine, Riboflavine, Pantoprazole [10] 
in-situ colloidal 
gels 
Clarithromycin, Furosemide, Ofloxacin [8, 10] 
Films 5-Flurouracil, Propranolol, Metoprolol [8, 10] 
 
Factors affecting gastric residence time of the floating drug 
delivery system  
Formulation factors  
Size of tablets  
Floating retention phenomenon of dosage forms in the stomach 
basically depends on the size of tablets. Small tablets are expelled 
rapidly from the stomach compared to large ones are emptied 
during the digestive phase. 
Density of tablets 
Density also considered as contributing factor affecting the gastric 
residence time of dosage form. A buoyant dosage with a density less 
than that of the gastric fluids would float as it is long enough from 
the pyloric sphincter, thus having more retention in the stomach for 
a longer period. Density tablets about 1.0 g/ml (usually considered 
as less dense than that of gastric contents) have been reported more 
effective. However, the floating force kinetics has shown that the 
bulk density of a dosage form would not be the crucial parameter 
affecting its buoyancy capabilities. 
Shape of tablets 
The shape of the dosage form is also considered as one of the 
affecting factors as it interferes with gastric residence time. Six 
different types of shapes viz. ring tetrahedron, cloverleaf, string, 
pellet, and disk) are screened in vivo for their gastric retention 
potential; during this study, the tetrahedron shape (each leg 2 cm 
long) rings (3.6 cm in diameter) passed nearly 100% retention at 24 h. 
Viscosity of polymers 
Drug release and floating characters of FDDS are majorly affected by 
the viscosity of different grade of polymers and their interaction. 
Low viscosity polymers (e. g., HPMC K100 LV) are found to be more 
beneficial than high viscosity polymers (e. g., HPMC K4M) in 
enhancing the floating properties of the dosage form. Moreover, a 




A study shows women have slower gastric emptying time in comparison 
with men. Mean ambulatory gastric retention time in men (3.4±0.4 h) is 
lower in comparison with their age and race with female counterparts 
(4.6±1.2 h), regardless of the weight, height and body surface. 
Age 
Lower gastric emptying time is also observed with high frequent in 
elderly than do in younger. Intra and inter-person variations are also 
Krishnamoorthy et al. 
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existing in gastric and intestinal transit time. Elderly people, especially 
those over 70 y have a significantly longer gastric retention time. 
Posture  
Upright position  
An upright position prolongs floating forms against postprandial 
emptying since the floating form remains above the gastric contents 
irrespective of its size [13]. Floating dosage forms show longer and 
reproducible gastric retention time while the conventional dosage forms 
tend to sink at the lower part of the distal stomach from where they are 
expelled through the pylorus by peristaltic movements. 
Supine position 
This position does not offer any reliable protection against early and 
erratic emptying. In supine subjects, large dosage forms (both 
conventional and floating) may experience longer retention. The 
gastric retention of floating forms appears to remain buoyant 
anywhere between the lesser and greater curvature of the stomach. 
On moving distally, these units may be swept away by the peristaltic 
movements that propel the gastric contents towards the pylorus, 
leading to a significant reduction in gastric retention time compared 
with upright subjects. 
Concomitant intake of drugs 
Different drugs with a concomitant intake like prokinetic agents (e. g., 
metoclopramide and cisapride), anticholinergic (e. g., atropine or 
propantheline), opiates (e. g., codeine) may affect the performance of the 
floating drug delivery system. The co-administration of GI motility 
decreasing drugs can increase gastric emptying time and vice versa. 
Feeding regimen 
Gastric residence time shows enhancement in the presence of food, 
leading to increased drug dissolution rate of the dosage form at the 
favorable site of absorption. A gastric retention time of about 4 to 10 
h has been reported after a diet of fats and proteins [26-28]. 
The mechanism associated with FDDS  
FDDS is one of the presidential approaches in achieving gastric 
retention with sufficient drug bioavailability. This system is selective 
for the drugs with an absorption window in the stomach or in the 
upper small intestine. This has a less density then gastric fluids and 
hence remain buoyant in the stomach without affecting gastric 
emptying rate for a prolonged period, and the drug is released 
slowly as a desired rate from the system. After the release of the 
drug, the residual system is expelled from the stomach. This results 
in an increased gastric retention time and better control on the 
fluctuation in plasma drug concentration [29-32]. 
Pharmacokinetic and pharmacodynamic aspects of FDDS  
Enhanced bioavailability 
FDDS has studied with excellence increase in bioavailability of 
certain drugs with low therapeutic window solely due to poor GI 
absorption due to various factors contributing to lower 
bioavailability. The drugs those considered with narrow absorption 
window, FDDS shown the possibility of with enhanced 
bioavailability of the compound to the specific site needed. The 
bioavailability of control release (CR) floating systems of Riboflavin 
and Levodopa are significantly enhanced in comparison to the 
administration of the conventional formulation. On the other hand, 
CR polymeric formulations of certain bisphosphonates, including 
alendronate, are absorbed directly from the stomach. However, the 
magnitude of this pathway remains modest even in the case where 
the prolonged gastric retention of the bisphosphonate in rats is 
produced by experimental/surgical means. It may be concluded that 
several different processes, related to absorption and transit of the 
drug in the gastrointestinal tract, act concomitantly and influence 
the magnitude of drug absorption.  
Enhanced first-pass biotransformation 
In a similar fashion to increased efficacy of active transporters exhibiting 
limited capacity activity, the pre-systemic metabolism of the tested 
compound has considerably increased cause of FDDS, if the drug is 
presented to the metabolic enzymes (cytochrome P450, in particular, 
CYP3A4) in a sustained manner, rather than by a bolus input. 
Improved bioavailability due to reduced P-glycoprotein (P-gp) 
activity in the duodenum 
In apparent contrast to the higher density of CYP3A4 at the upper part of 
the intestine, P-gp mRNA levels increase longitudinally along the 
intestine such that the highest levels are located in the colon. Therefore, 
for drugs that are P-gp substrate and do not undergo oxidative 
metabolism, such as Digoxin, floating systems may elevate absorption 
compared to the immediate and control release (CR) dosage forms. 
Reduced frequency of dosing 
The different studies reveal that the drugs those contributing relatively 
short biological half-life, slow input from sustained release and control 
release floating system flip-flop pharmacokinetics assured with reduced 
dosing frequency were observed. This feature is associated with 
improved patient compliance, and thereby improves therapy. 
Targeted therapy for local ailments in the upper GIT 
The prolonged and sustained administration of the drug from the 
floating systems to the stomach may be advantageous for local 
therapy in the stomach and the small intestine. 
Pharmacodynamic aspects of FDDS 
Reduced fluctuations of drug concentration 
Floating system of drug administration produces constant blood 
drug concentrations within a narrower range in comparison to the 
immediate release dosage forms on continuous input of the drug. 
Thus, fluctuations in drug effects are minimized, and concentration-
dependent adverse effects that are associated with peak 
concentrations can be prevented. This feature is especially 
advantageous for drugs with a narrow therapeutic index.  
Improved selectivity in receptor activation 
Minimization of fluctuations in drug concentration also makes it possible 
to obtain certain selectivity in the elicited pharmacological effect of drugs 
that activate different types of receptors at different concentrations. 
Reduced counter-activity of the body 
In many cases, the pharmacological response, which intervenes with 
the natural physiologic processes, provokes a rebound activity of the 
body that minimizes drug activity. Slow input of the drug into the 
body as in case of FDDS is shown to minimize the counter activity 
leading to higher drug efficiency.  
Minimized adverse activity at the colon 
Retention of the drug in the FDDS specifically in case of gastro 
retentive form at the stomach minimizes the amount of drug that 
reaches down the colon. Thus, undesirable activities of the drug in 
colon may be prevented. This pharmacodynamic aspect provides the 
rationale for floating formulation for beta-lactam antibiotics that are 
absorbed only from the small intestine and presence in the colon 
leads to the development of microorganisms [31]. 
Evaluation of floating drug delivery system  
Shape of tablets 
Compressed tablets designed for FDDS are examined under the 
magnifying lens for the determination of its shape consistency. 
Tablet dimensions 
As per official compendia, the thickness and diameter of tablets in 
FDDS form are measured using a calibrated Vernier callipers same 
with that of conventional tablets. Three tablets of each formulation 
are picked randomly, and thickness is measured individually. 
Determination of hardness of the tablet 
Randomly sampled twenty tablets in each batch of formulations 
should be used for the determination of hardness with the help of 
Monsanto type hardness tester. 
Krishnamoorthy et al. 
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Determination of weight variation 
Twenty tablets selected at random are weighed accurately, and the 
average weight of the tablet is calculated. Then the deviation of 
individual weight from the average weight is calculated. 
Determination of thickness of the tablet 
The individual crown to crown thickness of ten tablets is determined 
using slide calipers for each batch 
Measurement of floating capacity 
Three individual tablets are put in an individual flask containing 400 
ml of 0.1(N) HCL solutions. Then the time in minutes for each tablets 
to go from the bottom to the top of the flask (floating lag time) and 
the time for which tablets constantly float on the water surface 
(duration of floating) are measured. The sample mean and standard 
deviation are then calculated 
Measurement of the density of the formulation 
The apparent densities of the tablets are calculated from their 
volumes and masses in triplicate. The volume V of the cylindrical 
tablets are calculated from their height h and radius r (both 
determined with a micrometer gauge) using the mathematical 
equation for a cylinder (V = A × r2 × h). 
Determination of drug content in tablets 
Ten tablets from each batch are selected randomly and transferred 
to a 100 ml volumetric flask filled up with 0.1(N) HCL. Stir and Keep 
it aside for 2 h then take 1 ml from the volumetric flask and transfer 
it to the test tube. Samples are then filtered, suitably diluted and 
analyzed spectrophotometrically at a suitable wavelength [32, 33]. 
In vitro dissolution study 
The tablet was placed inside the dissolution vessel. 5 ml of sample is 
withdrawn at time intervals of 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10 h, and 12h 
or any other time intervals as needed. The volume of dissolution fluid 
adjusted to 900 ml by replacing fresh 5 ml of dissolution medium after 
each sampling. The release studies were conducted with “n” tablets, 
and the mean values are plotted versus time. Each sample is analyzed 
at maximum wavelength using UV visible spectrophotometer against a 
reagent blank and the corresponding concentration is determined 
from the respective calibration curve [34]. 
Buoyancy/Floating test 
The time between introduction of the dosage form and its buoyancy 
on the simulated gastric fluid and the time during which the dosage 
form remain buoyant are measured. The time taken for the dosage 
form to emerge on the surface of a medium called floating lag time 
(FLT) or buoyancy lag time (BLT) and total duration of time by 
which dosage form remain buoyant is called total floating time (TFT) 
[35]. 
Swelling study 
The swelling behavior of a dosage form is measured by studying its 
weight gain or water uptake. The dimensional changes could be 
measured in terms of the increase in tablet diameter and/or 
thickness over time. Water uptake can be measured in terms of 
percent weight gain, as given by the equation. 
 =  −	100 
Where,  
WU= Water uptake 
Wt = Weight of dosage form at time t.  
Wo = Initial weight of dosage form [35]. 
CONCLUSION  
Drug absorption in the gastrointestinal tract is a highly variable 
procedure and prolonging gastric retention of the dosage form that 
leads to extend the time for drug absorption. FDDS promises to be a 
potential approach for gastric retention. Numbers of commercial 
products and patents issues in these fields are the evidence of it. The 
aim is to improve the bioavailability of the drug with narrow 
absorption window in gastrointestinal tract region. By prolonging the 
drug resident time in GI region improves the solubility of drug that is 
less soluble in high pH and reduces drug waste, reduction in plasma 
level fluctuation. Although there are a number of difficulties to be 
worked out to achieve prolonged gastric retention, a large number of 
companies are focusing toward commercializing this technique. 
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